TopoTarget's Totect gets Priority Review

FDA accepted for filing and granted Priority Review to an NDA for Totect (formerly Topotect) dexrazoxane from TopoTarget (CSE:TOPO) to treat accidental extravasation of anthracycline chemotherapeutics...